Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:27:48.298Z.
Consensus retrieved: 2026-10-06T14:42:14.475Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:27:48.298Z.
Quote observation: 2026-10-06T18:25:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a3ccde1bd0df5c55ebc0148063105fff0bf751cb52a3071af3e3331f6001fbe
FORWARD PE RATIO
N/A
Oculis Holding AG
Market Cap
$495.66M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Oculis Holding AG (OCS) | $495.66M | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $502.60M | 19.95 |
| Puma Biotechnology, Inc. (PBYI)vs › | $487.34M | 25.20 |
| Evolus, Inc. (EOLS)vs › | $486.55M | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $509.99M | N/A |
| 908 Devices Inc. (MASS)vs › | $510.55M | N/A |
| Alpha Teknova, Inc. (TKNO)vs › | $478.24M | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $475.90M | N/A |
| Arvinas, Inc. (ARVN)vs › | $475.63M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in CHF, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
